Buprenorphine vs. morphine: impact on neonatal opioid withdrawal syndrome (NOWS) outcomes in a single center retrospective study

期刊论文
出版模式：

开放获取
发表日期：

2024年7月13日

查看全文

Saminathan Anbalagan,
Victoria Anderson,
Michael T. Favara,
Daniela Stark,
David Carola,
Kolawole Solarin,
Susan Adeniyi-Jones,
Walter K. Kraft,
Zubair H. Aghai

摘要

Objectives

To compare clinical outcomes for infants with neonatal opioid withdrawal syndrome (NOWS) treated with buprenorphine or morphine.

Study design

Retrospective study of infants born ≥35 weeks’ gestation and admitted to the NICU for NOWS treatment between 2011 and 2022. Length of treatment, length of stay in the hospital, and the need for secondary medications were compared between buprenorphine and morphine treated neonates. Multiple regression analysis was performed, adjusting for baseline differences and confounders.

Results

417 neonates were treated with morphine and 232 with buprenorphine. The buprenorphine group had shorter treatment days [−10.8 days; 95% CI: −8.08 to −13.53] and shorter hospital stay [−11.8 days; 95% CI: −8.83 to −14.78]. The buprenorphine group was no more likely to receive phenobarbital or clonidine (26% vs. 29%).

Conclusion

In this large single-center study, buprenorphine was associated with shorter lengths of treatment and hospital stay in the treatment of NOWS compared to morphine.